Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Monday morning,Benzinga reports. They currently have a $8.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Scotiabank started coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price on the stock. Roth Mkm reiterated a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $2.40 on Monday. The business’s 50 day moving average price is $2.23 and its 200 day moving average price is $2.00. The firm has a market cap of $63.66 million, a P/E ratio of -2.18 and a beta of 0.14. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.63. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after purchasing an additional 44,750 shares in the last quarter. Marshall Wace LLP purchased a new stake in Gain Therapeutics in the 4th quarter worth approximately $198,000. Northern Trust Corp boosted its position in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics in the 4th quarter worth approximately $65,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.